1. The Genome in a Three-Dimensional Context : Deciphering the Contribution of Noncoding Mutations at Enhancers to Blood Cancer
- Author
-
Rovirosa Mulet, Llorenç, Ramos-Morales, Alberto, Javierre, BM, and Universitat Autònoma de Barcelona
- Subjects
lcsh:Immunologic diseases. Allergy ,0301 basic medicine ,Spatial genome architecture ,Mini Review ,Immunology ,Context (language use) ,Computational biology ,Biology ,Genome ,spatial genome architecture ,DNA loops ,Blood cancer ,03 medical and health sciences ,0302 clinical medicine ,Untranslated Regions ,Genetic predisposition ,Enhancers ,Animals ,Humans ,Immunology and Allergy ,genetics ,hematopoietic malignancies ,Genetic Predisposition to Disease ,noncoding mutations and epimutations ,Epigenetics ,Enhancer ,Alleles ,Noncoding mutations and epimutations ,Genome, Human ,blood cancer ,Translation (biology) ,Genomics ,Hematopoietic malignancies ,Cell Transformation, Neoplastic ,Enhancer Elements, Genetic ,030104 developmental biology ,Hematologic Neoplasms ,Mutation ,Disease Progression ,enhancers ,3D chromatin organization ,lcsh:RC581-607 ,Genome architecture ,Genome-Wide Association Study ,030215 immunology - Abstract
Altres ajuts: AR-M is funded by the José Carreras Leukämie-Stiftung (08R/2019). BJ is funded by La Caixa Banking Foundation Junior Leader project (LCF/BQ/PI19/11690001), by the José Carreras Leukämie-Stiftung (08R/2019), and by the European Hematology Association Advance Research Grant. Associations between blood cancer and genetic predisposition, including both inherited variants and acquired mutations and epimutations, have been well characterized. However, the majority of these variants affect noncoding regions, making their mechanisms difficult to hypothesize and hindering the translation of these insights into patient benefits. Fueled by unprecedented progress in next-generation sequencing and computational integrative analysis, studies have started applying combinations of epigenetic, genome architecture, and functional assays to bridge the gap between noncoding variants and blood cancer. These complementary tools have not only allowed us to understand the potential malignant role of these variants but also to differentiate key variants, cell-types, and conditions from misleading ones. Here, we briefly review recent studies that have provided fundamental insights into our understanding of how noncoding mutations at enhancers predispose and promote blood malignancies in the context of spatial genome architecture.
- Published
- 2021